Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Executive Summary
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
You may also be interested in...
It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
BMS’s Bladder Cancer Program Sees Change In Fortunes With Opdivo Substudy Win
A cohort of patients in CheckMate-901 eligible for cisplatin chemotherapy showed OS and PFS improvements, after the company reported negative results in PD-L1-positive patients last year.
Nektar Restructures A Second Time, Focusing Squarely On Immunology
A year after reducing headcount by 70%, Nektar is trimming another 60% and looking to partner out cancer candidate NKTR-255 to focus on rezpeg for atopic dermatitis, with or without Lilly’s help.